These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 19562648

  • 1. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U.
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [Abstract] [Full Text] [Related]

  • 2. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U, Kowalski TJ.
    Vitam Horm; 2010 Jul; 84():415-48. PubMed ID: 21094910
    [Abstract] [Full Text] [Related]

  • 3. GPR119 agonists for the treatment of type 2 diabetes.
    Jones RM, Leonard JN, Buzard DJ, Lehmann J.
    Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
    [Abstract] [Full Text] [Related]

  • 4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY, Kim YS, Kim CH, Choi HS, Yang J, Park SH, Kim DH, Rhee JK.
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [Abstract] [Full Text] [Related]

  • 5. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T, Yoshida S.
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [Abstract] [Full Text] [Related]

  • 6. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
    Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W, Unett DJ, Xing C, Bossie S, Carroll C, Chu ZL, Grottick AJ, Hauser EK, Leonard J, Jones RM.
    J Med Chem; 2008 Sep 11; 51(17):5172-5. PubMed ID: 18698756
    [Abstract] [Full Text] [Related]

  • 7. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA, Wang Y, Broekema M, Rossi K, O'Connor S, Hong Z, Wu G, Malmstrom SE, Hung CP, LaMarre L, Chimalakonda A, Zhang L, Xin L, Cai H, Chu C, Boehm S, Zalaznick J, Ponticiello R, Sereda L, Han SP, Zebo R, Zinker B, Luk CE, Wong R, Everlof G, Li YX, Wu CK, Lee M, Griffen S, Miller KJ, Krupinski J, Robl JA.
    J Med Chem; 2014 Sep 25; 57(18):7499-508. PubMed ID: 25208139
    [Abstract] [Full Text] [Related]

  • 8. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU.
    Drug Discov Today; 2013 Dec 25; 18(23-24):1309-15. PubMed ID: 24060477
    [Abstract] [Full Text] [Related]

  • 9. GPR119 agonists 2009-2011.
    Buzard DJ, Lehmann J, Han S, Jones RM.
    Pharm Pat Anal; 2012 Jul 25; 1(3):285-99. PubMed ID: 24236842
    [Abstract] [Full Text] [Related]

  • 10. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN, Kurkin DV, Bakulin DA, Lomkina EM, Volotova EV.
    Usp Fiziol Nauk; 2015 Jul 25; 46(4):28-37. PubMed ID: 27183782
    [Abstract] [Full Text] [Related]

  • 11. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
    Cornall LM, Mathai ML, Hryciw DH, McAinch AJ.
    Expert Opin Investig Drugs; 2013 Apr 25; 22(4):487-98. PubMed ID: 23442069
    [Abstract] [Full Text] [Related]

  • 12. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
    Manaithiya A, Alam O, Sharma V, Javed Naim M, Mittal S, Khan IA.
    Bioorg Chem; 2021 Aug 25; 113():104998. PubMed ID: 34048996
    [Abstract] [Full Text] [Related]

  • 13. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B.
    Minerva Endocrinol; 2006 Jun 25; 31(2):133-47. PubMed ID: 16682937
    [Abstract] [Full Text] [Related]

  • 14. Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
    Furman B, Pyne N, Flatt P, O'Harte F.
    J Pharm Pharmacol; 2004 Dec 25; 56(12):1477-92. PubMed ID: 15563754
    [Abstract] [Full Text] [Related]

  • 15. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z.
    Curr Opin Drug Discov Devel; 2008 Jul 25; 11(4):512-32. PubMed ID: 18600568
    [Abstract] [Full Text] [Related]

  • 16. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH, Patten RK, Rodgers RJ, Proietto J, Hutchinson DS, McAinch AJ.
    Expert Opin Investig Drugs; 2024 Mar 25; 33(3):183-190. PubMed ID: 38372052
    [Abstract] [Full Text] [Related]

  • 17. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK, Holst JJ, Vilsbøll T.
    IDrugs; 2008 Jul 25; 11(7):497-501. PubMed ID: 18600596
    [Abstract] [Full Text] [Related]

  • 18. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K, Yoshitomi T, Ishimoto Y, Tanaka N, Takahashi K, Watanabe A, Chiba K.
    J Pharmacol Exp Ther; 2018 Dec 25; 367(3):509-517. PubMed ID: 30217957
    [Abstract] [Full Text] [Related]

  • 19. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Dec 25; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 20. GPR119 as a fat sensor.
    Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW.
    Trends Pharmacol Sci; 2012 Jul 25; 33(7):374-81. PubMed ID: 22560300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.